References
Ahrens, J., Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi, N., . . . Haeseler, G. (2009). The Nonpsychotropic Cannabinoid Cannabidiol Modulates and Directly Activates Alpha-1 and Alpha-1-Beta Glycine Receptor Function. Pharmacology, 83 (4), 217-222. doi:10.1159/000201556
Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review. (2016). Cannabis and Cannabinoid Research, 1 (1), 22-30. doi:10.1089/can.2015.0005
Aviello, G., Romano, B., Borrelli, F., Capasso, R., Gallo, L., Piscitelli, F., . . . Izzo, A. A. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. Journal of Molecular Medicine, 90 (8), 925-934. doi:10.1007/s00109-011-0856-x
Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib, M. (2017). The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacological Research, 119 , 358-370. doi:https://doi.org/10.1016/j.phrs.2017.02.022
Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci, 17 (3), 327-335. doi:10.31887/DCNS.2015.17.3/bbandelow
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., . . . Crippa, J. A. S. (2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients.Neuropsychopharmacology, 36 (6), 1219-1226. doi:10.1038/npp.2011.6
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., . . . Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.British journal of pharmacology, 134 (4), 845-852. doi:https://doi.org/10.1038/sj.bjp.0704327
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders.Neurotherapeutics, 12 (4), 825-836. doi:10.1007/s13311-015-0387-1
Bloechl-Daum, B., Deuson, R. R., Mavros, P., Hansen, M., & Herrstedt, J. (2006). Delayed Nausea and Vomiting Continue to Reduce Patients’ Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment. Journal of Clinical Oncology, 24 (27), 4472-4478. doi:10.1200/jco.2006.05.6382
Boggs, D. L., Surti, T., Gupta, A., Gupta, S., Niciu, M., Pittman, B., . . . Ranganathan, M. (2018). The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl), 235 (7), 1923-1932. doi:10.1007/s00213-018-4885-9
Bujak, J. K., Kosmala, D., Szopa, I. M., Majchrzak, K., & Bednarczyk, P. (2019). Inflammation, Cancer and Immunity—Implication of TRPV1 Channel. Frontiers in Oncology, 9 (1087). doi:10.3389/fonc.2019.01087
Burstein, S. (2015). Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorganic & Medicinal Chemistry, 23 (7), 1377-1385. doi:https://doi.org/10.1016/j.bmc.2015.01.059
Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012). Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors. Journal of Psychiatric Research, 46 (11), 1501-1510. doi:https://doi.org/10.1016/j.jpsychires.2012.08.012
Capano, A., Weaver, R., & Burkman, E. (2020). Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgraduate Medicine, 132 (1), 56-61. doi:10.1080/00325481.2019.1685298
Cathy M. Russo, M., & William G. Brose, M. (1998). Chronic Pain.Annual Review of Medicine, 49 (1), 123-133. doi:10.1146/annurev.med.49.1.123
Catterall, W. A. (2017). Forty Years of Sodium Channels: Structure, Function, Pharmacology, and Epilepsy. Neurochemical Research, 42 (9), 2495-2504. doi:10.1007/s11064-017-2314-9
Chu Sin Chung, P., & Kieffer, B. L. (2013). Delta opioid receptors in brain function and diseases. Pharmacology & Therapeutics, 140 (1), 112-120. doi:https://doi.org/10.1016/j.pharmthera.2013.06.003
ClinicalTrials. gov. Retrieved from https://clinicaltrials.gov/
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L. S., Martin-Santos, R., . . . Hallak, J. E. C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 25 (1), 121-130. doi:10.1177/0269881110379283
D’Souza, D. C., Cortes-Briones, J., Creatura, G., Bluez, G., Thurnauer, H., Deaso, E., . . . Skosnik, P. D. (2019). Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet Psychiatry, 6 (1), 35-45. doi:10.1016/S2215-0366(18)30427-9
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., . . . Di Marzo, V. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British journal of pharmacology, 163 (7), 1479-1494. doi:https://doi.org/10.1111/j.1476-5381.2010.01166.x
De Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M., Verde, R., Stott, C. G., . . . Di Marzo, V. (2013). Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. British journal of pharmacology, 168 (1), 79-102. doi:https://doi.org/10.1111/j.1476-5381.2012.02027.x
De Petrocellis, L., Orlando, P., Moriello, A. S., Aviello, G., Stott, C., Izzo, A. A., & Di Marzo, V. (2012). Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiologica, 204 (2), 255-266. doi:https://doi.org/10.1111/j.1748-1716.2011.02338.x
De Petrocellis, L., Vellani, V., Schiano-Moriello, A., Marini, P., Magherini, P. C., Orlando, P., & Di Marzo, V. (2008). Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8. Journal of Pharmacology and Experimental Therapeutics, 325 (3), 1007-1015. doi:10.1124/jpet.107.134809
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., . . . Wright, S. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine, 376 (21), 2011-2020. doi:10.1056/NEJMoa1611618
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., . . . Cilio, M. R. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.The Lancet Neurology, 15 (3), 270-278. doi:https://doi.org/10.1016/S1474-4422(15)00379-8
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., . . . Zuberi, S. M. (2018). Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. New England Journal of Medicine, 378 (20), 1888-1897. doi:10.1056/NEJMoa1714631
Di Marzo, V. (2008). The endocannabinoid system in obesity and type 2 diabetes. Diabetologia, 51 (8), 1356. doi:10.1007/s00125-008-1048-2
Di Marzo, V., Bifulco, M., & De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery, 3 (9), 771-784. doi:10.1038/nrd1495
Dunlop, B. W., & Nemeroff, C. B. (2007). The Role of Dopamine in the Pathophysiology of Depression. Archives of General Psychiatry, 64 (3), 327-337. doi:10.1001/archpsyc.64.3.327
Duran, M., Perez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., . . . Capella, D. (2010). Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol, 70 (5), 656-663. doi:10.1111/j.1365-2125.2010.03743.x
Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P., Wang, L., . . . Deutsch, D. G. (2015). Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)*. Journal of Biological Chemistry, 290 (14), 8711-8721. doi:https://doi.org/10.1074/jbc.M114.618447
Epidiolex. Retrieved from https://www.gwpharm.com/healthcare-professionals
Epilepsy Retrieved from https://www.who.int/news-room/fact-sheets/detail/epilepsy
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., . . . Steardo, L. (2011). Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement. PLoS One, 6 (12), e28668. doi:10.1371/journal.pone.0028668
Fagundo, A. B., de la Torre, R., Jiménez-Murcia, S., Agüera, Z., Pastor, A., Casanueva, F. F., . . . Fernández-Aranda, F. (2013). Modulation of the Endocannabinoids N-Arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans.PLoS One, 8 (6), e66387. doi:10.1371/journal.pone.0066387
FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease.
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., . . . Wiebe, S. (2014). ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia, 55 (4), 475-482. doi:https://doi.org/10.1111/epi.12550
Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., . . . Zuberi, S. M. (2017). Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.Epilepsia, 58 (4), 522-530. doi:https://doi.org/10.1111/epi.13670
Freedman, R. (2003). Schizophrenia. New England Journal of Medicine, 349 (18), 1738-1749. doi:10.1056/NEJMra035458
Freitas-Ferrari, M. C., Hallak, J. E. C., Trzesniak, C., Filho, A. S., Machado-de-Sousa, J. P., Chagas, M. H. N., . . . Crippa, J. A. S. (2010). Neuroimaging in social anxiety disorder: A systematic review of the literature. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34 (4), 565-580. doi:https://doi.org/10.1016/j.pnpbp.2010.02.028
Gallily, R., Even-Chena, T., Katzavian, G., Lehmann, D., Dagan, A., & Mechoulam, R. (2003). Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma, 44 (10), 1767-1773. doi:10.1080/1042819031000103917
Gharedaghi, M. H., Seyedabadi, M., Ghia, J.-E., Dehpour, A. R., & Rahimian, R. (2014). The role of different serotonin receptor subtypes in seizure susceptibility. Experimental Brain Research, 232 (2), 347-367. doi:10.1007/s00221-013-3757-0
Goddard, A. W., Ball, S. G., Martinez, J., Robinson, M. J., Yang, C. R., Russell, J. M., & Shekhar, A. (2010). Current perspectives of the roles of the central norepinephrine system in anxiety and depression.Depression and Anxiety, 27 (4), 339-350. doi:https://doi.org/10.1002/da.20642
Gottesmann, C. (2002). GABA mechanisms and sleep. Neuroscience, 111 (2), 231-239. doi:https://doi.org/10.1016/S0306-4522(02)00034-9
Granja, A. G., Carrillo-Salinas, F., Pagani, A., Gómez-Cañas, M., Negri, R., Navarrete, C., . . . Muñoz, E. (2012). A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis.Journal of Neuroimmune Pharmacology, 7 (4), 1002-1016. doi:10.1007/s11481-012-9399-3
Grimison, P., Mersiades, A., Kirby, A., Lintzeris, N., Morton, R., Haber, P., . . . Stockler, M. (2020). Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology, 31 (11), 1553-1560. doi:https://doi.org/10.1016/j.annonc.2020.07.020
Hallak, J. E. C., Machado-de-Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C., Chaves, C., . . . Zuardi, A. W. (2010). Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Brazilian Journal of Psychiatry, 32 , 56-61.
Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., & Westlund, K. N. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain, 20 (6), 936-948. doi:10.1002/ejp.818
Haustrate, A., Prevarskaya, N., & Lehen’kyi, V. y. (2020). Role of the TRPV Channels in the Endoplasmic Reticulum Calcium Homeostasis.Cells, 9 (2), 317.
Hillard, C. J. (2015). The Endocannabinoid Signaling System in the CNS: A Primer. Int Rev Neurobiol, 125 , 1-47. doi:10.1016/bs.irn.2015.10.001
Hillard, C. J. (2018). Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology, 43 (1), 155-172. doi:10.1038/npp.2017.130
Hsiao, Y.-T., Yi, P.-L., Li, C.-L., & Chang, F.-C. (2012). Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats.Neuropharmacology, 62 (1), 373-384. doi:https://doi.org/10.1016/j.neuropharm.2011.08.013
Jacobsson, S. O. P., Rongård, E., Stridh, M., Tiger, G., & Fowler, C. J. (2000). Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochemical Pharmacology, 60 (12), 1807-1813. doi:https://doi.org/10.1016/S0006-2952(00)00492-5
Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., . . . Tan, G. D. (2016). Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care, 39 (10), 1777-1786. doi:10.2337/dc16-0650
Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017). A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight, 2 (12). doi:10.1172/jci.insight.93760
Jeong, S., Yun, H. K., Jeong, Y. A., Jo, M. J., Kang, S. H., Kim, J. L., . . . Lee, D.-H. (2019). Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Letters, 447 , 12-23. doi:https://doi.org/10.1016/j.canlet.2019.01.011
Johal, H., Devji, T., Chang, Y., Simone, J., Vannabouathong, C., & Bhandari, M. (2020). Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 13 , 1179544120906461. doi:10.1177/1179544120906461
Johnson, E. L. (2019). Seizures and Epilepsy. Medical Clinics of North America, 103 (2), 309-324. doi:https://doi.org/10.1016/j.mcna.2018.10.002
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage, 39 (2), 167-179. doi:10.1016/j.jpainsymman.2009.06.008
Kalso, E., Edwards, J. E., Moore, R. A., & McQuay, H. J. (2004). Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain, 112 (3), 372-380. doi:https://doi.org/10.1016/j.pain.2004.09.019
Kaplan, J. S., Stella, N., Catterall, W. A., & Westenbroek, R. E. (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences, 114 (42), 11229-11234. doi:10.1073/pnas.1711351114
Kaumann, A. J., & Levy, F. O. (2006). 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther, 111 (3), 674-706. doi:10.1016/j.pharmthera.2005.12.004
Kenyon, J., Liu, W., & Dalgleish, A. (2018). Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. Anticancer Research, 38 (10), 5831-5835. doi:10.21873/anticanres.12924
Kesner, A. J., & Lovinger, D. M. (2020). Cannabinoids, Endocannabinoids and Sleep. Frontiers in Molecular Neuroscience, 13 (125). doi:10.3389/fnmol.2020.00125
Kevin P. Hill, 2,* Matthew D. Palastro,1 Brian Johnson,3 and Joseph W. Ditre4. (2017). Cannabis and Pain: A Clinical Review. Cannabis and Cannabinoid Research, 2 (1), 96-104. doi:10.1089/can.2017.0017
Kicman, A., & Toczek, M. (2020). The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease. International Journal of Molecular Sciences, 21 (18). doi:ARTN 6740
10.3390/ijms21186740
Kremer, M., Salvat, E., Muller, A., Yalcin, I., & Barrot, M. (2016). Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience, 338 , 183-206. doi:https://doi.org/10.1016/j.neuroscience.2016.06.057
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan-Wright, E. M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British journal of pharmacology, 172 (20), 4790-4805. doi:https://doi.org/10.1111/bph.13250
Lee, C.-Y., Wey, S.-P., Liao, M.-H., Hsu, W.-L., Wu, H.-Y., & Jan, T.-R. (2008). A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. International Immunopharmacology, 8 (5), 732-740. doi:https://doi.org/10.1016/j.intimp.2008.01.018
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., . . . Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.Translational Psychiatry, 2 (3), e94-e94. doi:10.1038/tp.2012.15
Leweke, F. M., Rohleder, C., Gerth, C. W., Hellmich, M., Pukrop, R., & Koethe, D. (2021). Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. Frontiers in Pharmacology, 12 (618). doi:10.3389/fphar.2021.614811
Ligresti, A., Bisogno, T., Matias, I., De Petrocellis, L., Cascio, M. G., Cosenza, V., . . . Di Marzo, V. (2003). Possible endocannabinoid control of colorectal cancer growth. Gastroenterology, 125 (3), 677-687. doi:https://doi.org/10.1016/S0016-5085(03)00881-3
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry, 41 , 9-14.
Linares, I. M. P., Guimaraes, F. S., Eckeli, A., Crippa, A. C. S., Zuardi, A. W., Souza, J. D. S., . . . Crippa, J. A. S. (2018). No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.Frontiers in Pharmacology, 9 (315). doi:10.3389/fphar.2018.00315
Long, L. E., Chesworth, R., Huang, X.-F., Wong, A., Spiro, A., McGregor, I. S., . . . Karl, T. (2012). Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. PLoS One, 7 (4), e34129. doi:10.1371/journal.pone.0034129
Luchicchi, A., & Pistis, M. (2012). Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol, 46 (2), 374-392. doi:10.1007/s12035-012-8299-0
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.Proceedings of the National Academy of Sciences, 97 (17), 9561-9566. doi:10.1073/pnas.160105897
MANDRUP-POULSEN, T. (2003). Beta Cell Death and Protection. Annals of the New York Academy of Sciences, 1005 (1), 32-42. doi:https://doi.org/10.1196/annals.1288.005
Manzanares, J., Julian, M. D., & Carrascosa, A. (2006). Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes. Current neuropharmacology, 4 (3), 239-257. doi:http://dx.doi.org/10.2174/157015906778019527
Martin, E. I., Ressler, K. J., Binder, E., & Nemeroff, C. B. (2009). The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology. Psychiatric Clinics of North America, 32 (3), 549-575. doi:https://doi.org/10.1016/j.psc.2009.05.004
Martinez-Aguirre, C., Carmona-Cruz, F., Velasco, A. L., Velasco, F., Aguado-Carrillo, G., Cuellar-Herrera, M., & Rocha, L. (2020). Cannabidiol Acts at 5-HT1A Receptors in the Human Brain: Relevance for Treating Temporal Lobe Epilepsy. Frontiers in Behavioral Neuroscience, 14 . doi:ARTN 611278
10.3389/fnbeh.2020.611278
Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E., Vincenzi, F., Ferreiro-Vera, C., . . . Franco, R. (2017). Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors. Frontiers in Pharmacology, 8 (744). doi:10.3389/fphar.2017.00744
Massi, P., Solinas, M., Cinquina, V., & Parolaro, D. (2013). Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 75 (2), 303-312. doi:https://doi.org/10.1111/j.1365-2125.2012.04298.x
Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., & Parolaro, D. (2006). The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cellular and Molecular Life Sciences CMLS, 63 (17), 2057-2066. doi:10.1007/s00018-006-6156-x
Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., & Parolaro, D. (2004). Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 308 (3), 838-845. doi:10.1124/jpet.103.061002
McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A., & Desprez, P.-Y. (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics, 6 (11), 2921-2927. doi:10.1158/1535-7163.mct-07-0371
McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A. J., Allison, J., . . . Desprez, P.-Y. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research and Treatment, 129 (1), 37-47. doi:10.1007/s10549-010-1177-4
McKallip, R. J., Jia, W., Schlomer, J., Warren, J. W., Nagarkatti, P. S., & Nagarkatti, M. (2006). Cannabidiol-Induced Apoptosis in Human Leukemia Cells: A Novel Role of Cannabidiol in the Regulation of p22<em><sup>phox</sup></em> and Nox4 Expression. Molecular Pharmacology, 70 (3), 897-908. doi:10.1124/mol.106.023937
McPartland, J. M., Glass, M., & Pertwee, R. G. (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. British journal of pharmacology, 152 (5), 583-593. doi:https://doi.org/10.1038/sj.bjp.0707399
Melzack, R., & Wall, P. D. (1965). Pain Mechanisms: A New Theory.Science, 150 (3699), 971-979. doi:10.1126/science.150.3699.971
Michelle G. Craske, Ph.D. ,, Scott L. Rauch, M.D. ,, Robert Ursano, M.D. ,, Jason Prenoveau, Ph.D. ,, Daniel S. Pine, M.D. , and, & Richard E. Zinbarg, Ph.D. (2011). What Is an Anxiety Disorder? FOCUS, 9 (3), 369-388. doi:10.1176/foc.9.3.foc369
Millar, S. A., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.Frontiers in Pharmacology, 9 . doi:ARTN 1365
10.3389/fphar.2018.01365
Mills, S. E. E., Nicolson, K. P., & Smith, B. H. (2019). Chronic pain: a review of its epidemiology and associated factors in population-based studies. British Journal of Anaesthesia, 123 (2), e273-e283. doi:10.1016/j.bja.2019.03.023
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry, 10 (1), 79-104. doi:10.1038/sj.mp.4001556
Mlost, J., Bryk, M., & Starowicz, K. (2020). Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action.International Journal of Molecular Sciences, 21 (22). doi:ARTN 8870
10.3390/ijms21228870
Morales, P., Reggio, P. H., & Jagerovic, N. (2017). An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol.Frontiers in Pharmacology, 8 (422). doi:10.3389/fphar.2017.00422
Moreno, E., Cavic, M., Krivokuca, A., Casadó, V., & Canela, E. (2019). The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet? Frontiers in Pharmacology, 10 (339). doi:10.3389/fphar.2019.00339
Mouslech, Z., & Valla, V. (2009). Endocannabinoid system: An overview of its potential in current medical practice. Neuro endocrinology letters, 30 2 , 153-179.
Mukhopadhyay, P., Mohanraj, R., Bátkai, S., & Pacher, P. (2008). CB1 Cannabinoid Receptor Inhibition: Promising Approach for Heart Failure?Congestive Heart Failure, 14 (6), 330-334. doi:https://doi.org/10.1111/j.1751-7133.2008.00016.x
Murillo-Rodriguez, E., Blanco-Centurion, C., Sanchez, C., Daniele, P., & Shiromani, P. J. (2003). Anandamide Enhances Extracellular Levels of Adenosine and Induces Sleep: An In Vivo Microdialysis Study.Sleep, 26 (8), 943-947. doi:10.1093/sleep/26.8.943
Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015). Emerging drugs for the treatment of anxiety. Expert Opinion on Emerging Drugs, 20 (3), 393-406. doi:10.1517/14728214.2015.1049996
Mustafa, N. (2015). TRPV1 Channel: A Potential Drug Target for Treating Epilepsy. Current neuropharmacology, 13 (2), 239-247. doi:http://dx.doi.org/10.2174/1570159X13666150216222543
Nemeroff, C. B. (2003). The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacology bulletin, 37 (4), 133-146.
Nichols, J. M., & Kaplan, B. L. F. (2020). Immune Responses Regulated by Cannabidiol. Cannabis and Cannabinoid Research, 5 (1), 12-31. doi:10.1089/can.2018.0073
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ‘N of 1’ studies.Anaesthesia, 59 (5), 440-452. doi:https://doi.org/10.1111/j.1365-2044.2004.03674.x
O’Sullivan, S. E., Sun, Y., Bennett, A. J., Randall, M. D., & Kendall, D. A. (2009). Time-dependent vascular actions of cannabidiol in the rat aorta. European Journal of Pharmacology, 612 (1), 61-68. doi:https://doi.org/10.1016/j.ejphar.2009.03.010
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017). The endocannabinoid system as a target for novel anxiolytic drugs. Neuroscience & Biobehavioral Reviews, 76 , 56-66. doi:https://doi.org/10.1016/j.neubiorev.2016.12.033
Pava, M. J., Makriyannis, A., & Lovinger, D. M. (2016). Endocannabinoid Signaling Regulates Sleep Stability. PLoS One, 11 (3), e0152473. doi:10.1371/journal.pone.0152473
Peng, J., & Li, Y.-J. (2010). The vanilloid receptor TRPV1: Role in cardiovascular and gastrointestinal protection. European Journal of Pharmacology, 627 (1), 1-7. doi:https://doi.org/10.1016/j.ejphar.2009.10.053
Perez-Reyes, E. (2003). Molecular Physiology of Low-Voltage-Activated T-type Calcium Channels. Physiological Reviews, 83 (1), 117-161. doi:10.1152/physrev.00018.2002
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British journal of pharmacology, 153 (2), 199-215. doi:https://doi.org/10.1038/sj.bjp.0707442
Philip McGuire, F.R.C.Psych., F.Med.Sci. ,, Philip Robson, M.R.C.P., F.R.C.Psych. ,, Wieslaw Jerzy Cubala, M.D., Ph.D. ,, Daniel Vasile, M.D., Ph.D. ,, Paul Dugald Morrison, Ph.D., M.R.C.Psych. ,, Rachel Barron, B.Vet.Med., M.R.C.V.S. ,, . . . Stephen Wright, F.R.C.P., F.F.P.M. (2018). Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry, 175 (3), 225-231. doi:10.1176/appi.ajp.2017.17030325
Piomelli, D. (2003). The molecular logic of endocannabinoid signalling.Nature Reviews Neuroscience, 4 (11), 873-884. doi:10.1038/nrn1247
PPARs and the Cardiovascular System. (2009). Antioxidants & Redox Signaling, 11 (6), 1415-1452. doi:10.1089/ars.2008.2280
Quigley, C. (2005). The role of opioids in cancer pain. BMJ, 331 (7520), 825-829. doi:10.1136/bmj.331.7520.825
Ramer, R., & Hinz, B. (2008). Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1. JNCI: Journal of the National Cancer Institute, 100 (1), 59-69. doi:10.1093/jnci/djm268
Ramer, R., Merkord, J., Rohde, H., & Hinz, B. (2010). Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochemical Pharmacology, 79 (7), 955-966. doi:https://doi.org/10.1016/j.bcp.2009.11.007
Ramer, R., Rohde, A., Merkord, J., Rohde, H., & Hinz, B. (2010). Decrease of Plasminogen Activator Inhibitor-1 May Contribute to the Anti-Invasive Action of Cannabidiol on Human Lung Cancer Cells.Pharmaceutical Research, 27 (10), 2162-2174. doi:10.1007/s11095-010-0219-2
Rao, K. V., & Faso, A. (2012). Chemotherapy-induced nausea and vomiting: optimizing prevention and management. American health & drug benefits, 5 (4), 232-240.
Ressler, K. J., & Nemeroff, C. B. (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety, 12 (S1), 2-19. doi:https://doi.org/10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi-Goffer, S., Fletcher, P., . . . Parker, L. (2012). Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus. British journal of pharmacology, 165 (8), 2620-2634. doi:https://doi.org/10.1111/j.1476-5381.2011.01621.x
Ross, H. R., Napier, I., & Connor, M. (2008). Inhibition of Recombinant Human T-type Calcium Channels by &#x394;<sup>9</sup>-Tetrahydrocannabinol and Cannabidiol *. Journal of Biological Chemistry, 283 (23), 16124-16134. doi:10.1074/jbc.M707104200
Ruiz-Medina, J., Ledent, C., & Valverde, O. (2011). GPR3 orphan receptor is involved in neuropathic pain after peripheral nerve injury and regulates morphine-induced antinociception. Neuropharmacology, 61 (1), 43-50. doi:https://doi.org/10.1016/j.neuropharm.2011.02.014
Russo, E. B. (2007). History of Cannabis and Its Preparations in Saga, Science, and Sobriquet. Chemistry & Biodiversity, 4 (8), 1614-1648. doi:https://doi.org/10.1002/cbdv.200790144
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Neurochemical Research, 30 (8), 1037-1043. doi:10.1007/s11064-005-6978-1
Russo, E. B., Guy, G. W., & Robson, P. J. (2007). Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis-Based Medicine. Chemistry & Biodiversity, 4 (8), 1729-1743. doi:https://doi.org/10.1002/cbdv.200790150
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N.-O., Leonova, J., . . . Greasley, P. J. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British journal of pharmacology, 152 (7), 1092-1101. doi:https://doi.org/10.1038/sj.bjp.0707460
Sativex®. Retrieved from https://www.gwpharm.com/healthcare-professionals/sativex
Schuelert, N., & McDougall, J. J. (2011). The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci Lett, 500 (1), 72-76. doi:10.1016/j.neulet.2011.06.004
Scuderi, C., De Filippis, D., Iuvone, T., Blasio, A., Steardo, A., & Esposito, G. (2009). Cannabidiol in Medicine: A Review of its Therapeutic Potential in CNS Disorders. Phytotherapy Research, 23 (5), 597-602. doi:10.1002/ptr.2625
Scuderi, C., Steardo, L., & Esposito, G. (2014). Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement.Phytotherapy Research, 28 (7), 1007-1013. doi:https://doi.org/10.1002/ptr.5095
Seltzer, E. S., Watters, A. K., MacKenzie, D., Granat, L. M., & Zhang, D. (2020). Cannabidiol (CBD) as a Promising Anti-Cancer Drug.Cancers, 12 (11), 3203.
Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente journal, 23 , 18-041. doi:10.7812/TPP/18-041
Shannon, S., & Opila-Lehman, J. (2016). Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. The Permanente journal, 20 (4), 16. doi:10.7812/TPP/16-005
Shin, H.-S. (2006). T-type Ca2+ channels and absence epilepsy.Cell Calcium, 40 (2), 191-196. doi:https://doi.org/10.1016/j.ceca.2006.04.023
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020). Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Curr Addict Rep, 7 (3), 405-412. doi:10.1007/s40429-020-00326-8
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules, 24 (8). doi:ARTN 1459
10.3390/molecules24081459
SREEVALSAN, S., JOSEPH, S., JUTOORU, I., CHADALAPAKA, G., & SAFE, S. H. (2011). Induction of Apoptosis by Cannabinoids in Prostate and Colon Cancer Cells Is Phosphatase Dependent. Anticancer Research, 31 (11), 3799-3807.
Stanley, C. P., Hind, W. H., & O’Sullivan, S. E. (2013). Is the cardiovascular system a therapeutic target for cannabidiol?British Journal of Clinical Pharmacology, 75 (2), 313-322. doi:https://doi.org/10.1111/j.1365-2125.2012.04351.x
State Medical Marijuana/Cannabis Program Laws. (2021). Retrieved from https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx
Steffens, S., & Pacher, P. (2012). Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies. British journal of pharmacology, 167 (2), 313-323. doi:https://doi.org/10.1111/j.1476-5381.2012.02042.x
Suraev, A., Grunstein, R. R., Marshall, N. S., D’Rozario, A. L., Gordon, C. J., Bartlett, D. J., . . . Hoyos, C. M. (2020). Cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (’CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. Bmj Open, 10 (5), e034421. doi:10.1136/bmjopen-2019-034421
Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan-Wright, E. M., & Laprairie, R. B. (2019). Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. British journal of pharmacology, 176 (10), 1455-1469. doi:https://doi.org/10.1111/bph.14440
Thiele, E. A., Bebin, E. M., Bhathal, H., Jansen, F. E., Kotulska, K., Lawson, J. A., . . . Group, G. S. (2021). Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurology, 78 (3), 285-292. doi:10.1001/jamaneurol.2020.4607
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.British journal of pharmacology, 150 (5), 613-623. doi:https://doi.org/10.1038/sj.bjp.0707133
Touw, M. (1981). The Religious and Medicinal Uses of Cannabis in China, India and Tibet. Journal of Psychoactive Drugs, 13 (1), 23-34. doi:10.1080/02791072.1981.10471447
Tovote, P., Fadok, J. P., & Lüthi, A. (2015). Neuronal circuits for fear and anxiety. Nature Reviews Neuroscience, 16 (6), 317-331. doi:10.1038/nrn3945
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., . . . Wang, S.-J. (2015). A classification of chronic pain for ICD-11. Pain, 156 (6), 1003-1007. doi:10.1097/j.pain.0000000000000160
Tsuboi, K., Uyama, T., Okamoto, Y., & Ueda, N. (2018). Endocannabinoids and related N-acylethanolamines: biological activities and metabolism.Inflammation and Regeneration, 38 (1), 28. doi:10.1186/s41232-018-0086-5
Urits, I., Gress, K., Charipova, K., Habib, K., Lee, D., Lee, C., . . . Viswanath, O. (2020). Use of cannabidiol (CBD) for the treatment of chronic pain. Best Practice & Research Clinical Anaesthesiology, 34 (3), 463-477. doi:https://doi.org/10.1016/j.bpa.2020.06.004
Vasko, M. R. (2009). Inflammatory Pain. In M. D. Binder, N. Hirokawa, & U. Windhorst (Eds.), Encyclopedia of Neuroscience (pp. 1952-1955). Berlin, Heidelberg: Springer Berlin Heidelberg.
Vigil, J. M., Stith, S. S., Diviant, J. P., Brockelman, F., Keeling, K., & Hall, B. (2018). Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions.Medicines, 5 (3), 75.
Vilela, L. R., Lima, I. V., Kunsch, É. B., Pinto, H. P. P., de Miranda, A. S., Vieira, É. L. M., . . . Moreira, F. A. (2017). Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels.Epilepsy & Behavior, 75 , 29-35. doi:https://doi.org/10.1016/j.yebeh.2017.07.014
von Wrede, R., Helmstaedter, C., & Surges, R. (2021). Cannabidiol in the Treatment of Epilepsy. Clinical Drug Investigation . doi:10.1007/s40261-021-01003-y
Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., & Gallily, R. (2006). Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity, 39 (2), 143-151. doi:10.1080/08916930500356674
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2008). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology, 54 (1), 244-249. doi:https://doi.org/10.1016/j.neuropharm.2007.06.029
Wheless, J. W., Dlugos, D., Miller, I., Oh, D. A., Parikh, N., Phillips, S., . . . Investigators, I.-.-S. (2019). Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy.Cns Drugs, 33 (6), 593-604. doi:10.1007/s40263-019-00624-4
White, C. M. (2019). A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential. Journal of Clinical Pharmacology, 59 (7), 923-934. doi:10.1002/jcph.1387
Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., . . . Rogers, M. J. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proceedings of the National Academy of Sciences, 106 (38), 16511-16516. doi:10.1073/pnas.0902743106
Wu, H.-Y., Chu, R.-M., Wang, C.-C., Lee, C.-Y., Lin, S.-H., & Jan, T.-R. (2008). Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8.Toxicology and Applied Pharmacology, 226 (3), 260-270. doi:https://doi.org/10.1016/j.taap.2007.09.012
Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S.-R., Willenbring, D., . . . Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. Journal of Experimental Medicine, 209 (6), 1121-1134. doi:10.1084/jem.20120242
Yang, K.-H., Galadari, S., Isaev, D., Petroianu, G., Shippenberg, T. S., & Oz, M. (2010). The Nonpsychoactive Cannabinoid Cannabidiol Inhibits 5-Hydroxytryptamine<sub>3A</sub> Receptor-Mediated Currents in <em>Xenopus laevis</em> Oocytes. Journal of Pharmacology and Experimental Therapeutics, 333 (2), 547-554. doi:10.1124/jpet.109.162594
Yokoe, T., Hayashida, T., Nagayama, A., Nakashoji, A., Maeda, H., Seki, T., . . . Kitagawa, Y. (2019). Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. The Oncologist, 24 (6), e347-e357. doi:https://doi.org/10.1634/theoncologist.2018-0140
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimaraes, F. S. (1993). Effects of Ipsapirone and Cannabidiol on Human Experimental Anxiety.Journal of Psychopharmacology, 7 (1), 82-88. doi:Doi 10.1177/026988119300700112
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. The Journal of Clinical Psychiatry, 56 (10), 485-486.
Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017). Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Frontiers in Pharmacology, 8 (259). doi:10.3389/fphar.2017.00259